RENO, Nev., May 02, 2007 (BUSINESS WIRE) -- Lifeline Biotechnologies, Inc.
(Pink Sheets:LBTN) today announced that it has entered into final negotiations
for the final development of the computer software system, the related
technology is the basis for its First Warning System(TM). The First Warning
System(TM) is designed to assist in the early detection of breast cancer.
Jim Holmes, Lifeline's CEO stated, "We are in the final stages of negotiation
with a major southeast Asian based university to complete development of the
software technology which provides the capability of the Company's First Warning
System(TM) to assist in the early detection of breast cancer. Lifeline has been
working with engineers at the university for several years on an informal basis
and a contract for a formal arrangement will be concluded. The software
development is expected to be completed near term. Upon completion of the
development involving the analysis of approximately 100 to 150 patient data from
women previously tested using Lifeline's First Warning System(TM), additional
clinical testing will be undertaken in order to validate this cutting edge
technology. To date, the development has indicated a potential breakthrough in
identifying breast cancer and the false positives and false negatives have been
within acceptable levels."
Share Exchange, Series B Convertible Preferred for Common Shares
The cut-off date, for the previously announced exchange of series B preferred
stock for common stock, for shareholders to submit their common shares to
Lifeline's Transfer Agent, OTC Corporate Stock Transfer, Jericho, NY, has been
extended to May 18, 2007. The exchange is for one share of preferred, valued at
$1.00 each for each 1600 shares of common stock submitted. The value of the
common stock is $.000625 per share, a premium over the current market price. To
qualify for the exchange, shareholders must submit a minimum of 100,000 common
shares. The Series B Preferred Stock is valued at $1.00 per share for future
conversion purposes. The Company will be sending an Information Statement
disclosing the terms and conditions of the exchange. In addition, particulars
concerning the exchange will be posted on Lifeline's website www.lbtn.com.
About Lifeline Biotechnologies, Inc.
Lifeline Biotechnologies, Inc. has recently reacquired the First Warning
System(TM) which it had sold in 2006. The Company will focus on completing the
development of the First Warning System(TM), designed to assist in the early
detection of breast cancer. The underlying technology, upon which the First
Warning System(TM) is based, holds the possibility of eliminating over 90% of
unnecessary breast biopsies performed each year providing a potential savings of
up to $2.8 billion annually. Additionally, the First Warning System(TM) could
conceivably eliminate the need for suggested MRIs, a savings of another $1.3
billion. Of the approximately $138 billion spent on cancer each year, Lifeline
could potentially save the healthcare industry up to $4.1 billion annually. Upon
successful completion of the development of the First Warning System(TM),
conducting clinical trials and obtaining FDA pre-marketing clearance, Lifeline
will commence marketing its breast cancer early detection system More
information is available at the Company's website: www.lbtn.com.
Safe Harbor: This release includes forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 27E of the Securities
Act of 1934. Statements contained in this release that are not historical facts
may be deemed to be forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual performance and
results may differ materially from that projected or suggested herein due to
certain risks and uncertainties including, without limitation, ability to obtain
financing and regulatory and shareholder approval for anticipated actions.
To automatically receive instant updates, press releases, and other information
on this and other Big Apple Consulting USA companies, please visit
www.bigappleconsulting.com/compro.php and download your FREE copy of Big Apple
ComPro.
SOURCE: Lifeline Biotechnologies, Inc.
CONTACT: Lifeline Biotechnologies, Inc.Rodney Marvel, Investor Relations1-866-THE-APPL(E)www.lbtn.com
News 
Market Data 
Discover 
AI
